Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

PaperCitations, authors & open-access status

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 335 citations, 2015 year and closed oa status.

335
Citations
2015
Year
closed
OA Status

Related on ScholarIQ

Robert S. Kahn
Author
The Lancet Oncology
Journal
Lymphoma Diagnosis and Treatment
Topic
Lymphoma Diagnosis and Treatment
Topic
Chronic Lymphocytic Leukemia Research
Topic
HER2/EGFR in Cancer Research
Topic
470M+ articles · free account